Citrate-theophylline-adenine-dipyridamol buffer is preferable to citrate buffer as an anticoagulant for flow cytometric measurement of platelet activation

Clinical Chemistry

Volumn 45, Issue 11, 1999, Pages 2030-2033

  Neufeld, Margitta ^a   Nowak Göttl, Ulrike ^a   Junker, Ralf ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTICOAGULANT AGENT; BUFFER; CALCIUM ION; CITRIC ACID; DIPYRIDAMOLE; THEOPHYLLINE;

ARTICLE; CALCIUM BLOOD LEVEL; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE;

EID: 0032710308     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.11.2030     Document Type: Article

References (16)

1. 1. Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987;10:998-1006.
2. 2. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
3. 3. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.
4. 4. Tschoepe D, Rösen P, Gries FA. The role of the megakaryocyte-platelet system for diabetic angiopathy: is metabolic control preventive therapy enough? Thromb Haemorrh Disord 1992;6:1-8.
5. 5. Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, Hacke W. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998;80:298-301.
6. 6. Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88: 37-42.
7. 7. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
8. 8. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75: 128-38.
9. 9. Tschoepe D, Rosen P, Schwippert B, Kehrel B, Schauseil S, Esser J, Gries FA. Platelet analysis using flow cytometric procedures. Platelets 1990;1: 127-33.
10. 10. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998;79:885-96.
11. 11. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993;70:659-66.
12. 12. Ray MJ, Carroll PA, Just SJ, Hawson GA. A low volume container suitable for monitoring the aPTT of heparinized patients. Blood Coagul Fibrinolysis 1993;4:805-7.
13. 13. Faraday N, Goldschmidt CP, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994;123:728-40.
14. 14. Nieuwenhuis HK, van Oosterhout JJ, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-liKe granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987;70:838-45.
15. 15. Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost 1995;21:146-51.
16. 16. Patscheke H. Shape and functional properties of human platelets washed with acid citrate. Haemostasia 1981;10:14-27.